Research News

---

Topic: Hormonal Therapies (view all topics)

Tags for topic Hormonal Therapies:

• After surgery (also called "adjuvant")
• Arimidex
• Aromasin
• Aromatase Inhibitors
• Before surgery (also called "neoadjuvant")
• Evista
• Fareston
• Faslodex
• Femara
• Not applicable (no surgery)
• Planning Hormonal Therapy
• Prophylactic (to lower risk if you've never been diagnosed with breast cancer)
• Selective Estrogen Receptor Modulators
• Tamoxifen

View articles by month and year

• Femara After Five Years of Tamoxifen Reduces Recurrence Risk

  Published on March 11, 2008 at 12:00 am

  • Tags: Femara, Tamoxifen, and After surgery (also called "adjuvant")

  Taking the aromatase inhibitor Femara (chemical name: letrozole) after taking tamoxifen for 5 years reduced the risk of the breast cancer coming back (recurrence), compared to not taking Femara after tamoxifen, even when Femara was started up to 7 years after tamoxifen.

• High Estrogen Levels May Lead to Recurrence

  Published on March 6, 2008 at 12:00 am

  • Tags: Arimidex, Aromasin, Femara, Tamoxifen, After surgery (also called "adjuvant"), and Aromatase Inhibitors

  Women diagnosed with early-stage breast cancer that came back (recurred) had higher blood estrogen levels than women diagnosed with early-stage breast cancer that didn't come back.

• Tamoxifen Plus Removing Ovaries Improves Survival for Premenopausal Women

  Published on January 11, 2008 at 12:00 am

  • Tags: Lumpectomy, Mastectomy, Prophylactic Ovary Removal, Tamoxifen, After surgery (also called "adjuvant"), Planning Hormonal Therapy, and Planning Surgery

  Removing the ovaries and taking tamoxifen after breast cancer surgery had benefits for premenopausal women shows a new study done in Vietnam and China.

• Tamoxifen and Chemo Reduce Risk of New, Second Cancer

  Published on December 25, 2007 at 12:00 am

  • Tags: Standard, Tamoxifen, and After surgery (also called "adjuvant")

  Tamoxifen and chemotherapy reduce the risk of developing a new, second breast cancer in the other breast.

• Arimidex More Effective Than Tamoxifen for Postmenopausal Women

  Published on December 17, 2007 at 12:00 am

  • Tags: Arimidex, Tamoxifen, After surgery (also called "adjuvant"), and Planning Hormonal Therapy

  Another year of results from the ATAC trial continues to show that Arimidex has more benefits than tamoxifen for post-menopausal women diagnosed with early-stage, hormone-receptor-positive breast cancer.

• Postmenopausal Women Benefit from Longer Hormonal Therapy

  Published on December 11, 2007 at 12:00 am

  • Tags: Arimidex, Femara, Tamoxifen, After surgery (also called "adjuvant"), and Planning Hormonal Therapy

  Taking Arimidex for 3 years after 5 years of tamoxifen reduced the risk of the cancer coming back in women diagnosed with hormone-receptor-positive breast cancer.

• Different Hormonal Therapies Cause Different Side Effects

  Published on November 14, 2007 at 12:00 am

  • Tags: Aromasin, Tamoxifen, and After surgery (also called "adjuvant")

  Hormonal therapy medicines used to reduce the risk of recurrence have different side effects.

• Chemotherapy and Aromatase Inhibitors Can Cause Bone Loss

  Published on September 19, 2007 at 12:00 am

  • Tags: Arimidex, Aromasin, Femara, After surgery (also called "adjuvant"), and Aromatase Inhibitors

  A new study provides more evidence that bone loss is a significant risk for women who receive chemotherapy and/or an aromatase inhibitor to treat breast cancer.

• Women Stop Taking Hormonal Therapy Too Soon Because of Side Effects

  Published on September 6, 2007 at 12:00 am

  • Tags: Arimidex, Aromasin, Femara, Tamoxifen, After surgery (also called "adjuvant"), and Aromatase Inhibitors

  Side effects cause many women to stop taking hormonal therapy medicine earlier than prescribed a new study reports.

• Hormonal Therapy Medicines Have Improved Survival

  Published on April 23, 2007 at 12:00 am

  • Tags: Arimidex, Aromasin, Femara, Tamoxifen, After surgery (also called "adjuvant"), Aromatase Inhibitors, and Planning Hormonal Therapy

  Hormone-receptor-positive breast cancer survival rates have increased faster than survival rates for hormone-receptor-negative breast cancer.